Subject Data Rights

BACKGROUND

Establishment Labs (“ESTA, We, Us, Our”) understands that your privacy is important to you and that you care about how your personal data is used. We respect and value the privacy of all of our customers, clients, and website visitors and will only collect and use personal data in a lawful and transparent manner, as set out in our Privacy Notice, available from https://establishmentlabs.com/privacy-policy . As a ‘data subject’ you have a number of rights under the law with respect to our use of your personal data. This Policy sets out those rights, explains them in clear terms, and provides guidelines on how to exercise them.

1. Information About Us

Establishment Labs® S.A.
Coyol Free Zone, B15
Alajuela, Costa Rica

+506 2434-2400

European Distribution Center Motiva BV
Nijverheidsstraat 96
2160 Wommelgem
Belgium
VAT BE 0881.512.541 RPM/RPR Antwerp

+32 3 432 41 70

2. What Does This Policy Cover?

Under data protection law, including key legislation such as the UK GDPR and Data Protection Act 2018 and any successor legislation, (collectively, “the Data Protection Legislation”) individuals have important rights designed to protect them and their personal data.

3. What Is Personal Data?

Personal data is defined by the Data Protection Legislation as ‘any information relating to a person who can be directly or indirectly identified by reference to an identifier’.

In simpler terms, personal data is any information about you that enables you to be identified. Personal data covers obvious information such as your name and contact details, but it also covers less obvious information such as identification numbers, electronic location data, and other online identifiers. The personal data that we use is set out in our Privacy Notice.

4. What Are My Rights?

(Summary) Data Protection Legislation sets out your key rights as a ‘data subject’ as follows:

  1. The right to be informed;
  2. The right of access;
  3. The right to rectification;
  4. The right to erasure;
  5. The right to restrict processing;
  6. The right to data portability;
  7. The right to object; and
  8. Rights in relation to automated decision-making and profiling.

dpo@establishmentlabs.com.

5. The Right to Be Informed

You have the right to be informed about our collection and use of your personal data. The information we provide must include details of the purpose or purposes for which your data is used, how long we keep it, and who (if anyone) it will be shared with.

This important privacy information is provided in our Privacy Notice. Additional information about your rights is also provided here, in this Policy.

If we collect data directly from you, this privacy information will be provided at the time of collection. We will ask you to read our Privacy Notice and provide Consent to indicate that you have read it and accepted it when visiting our website or when registering for an account.

6. The Right of Access

This right, also known as ‘subject access’ gives you the right to obtain a copy of any personal data that we hold about you as well as other supporting information.

This right is designed to help you understand how and why we use your data, and to check that we are using it lawfully.

You can exercise this right by making a ‘subject access request’. A subject access request can be made orally or in writing. The more detail you can provide, the easier it will be for us to respond quickly. While there is no prescribed format for such requests, a Subject Access Request Form is available https://establishment-labs.privacy.saymine.io/Motiva for you to use when making a request or you may submit a request to dpo@establishmentlabs.com.

We are required by law to respond to a subject access request within one calendar month of receipt (or, where we request proof of identification or a fee (see below), within one calendar month of receipt of that). We may also need to ask you for further information to understand the scope and nature of your request, and if we do so, the time limit for our response will be paused until you provide the necessary clarification. In certain limited cases, such as where your request is complex or you have made multiple requests, this period may be extended by up to two months; however, you will be kept informed at all times.

There is not normally a fee payable for a subject access request. For ‘manifestly unfounded or excessive’ requests, however, we are permitted to charge a ‘reasonable fee’ that covers our costs. Alternatively, in some limited circumstances, we may be permitted to refuse your request.

7. The Right to Rectification

Under the Data Protection Legislation, you have the right to have inaccurate personal data corrected, or incomplete personal data completed.

As a ‘data controller’ we are to take all reasonable steps to ensure that personal data we hold is accurate and, where necessary, kept up to date. Your right to rectification is closely tied to this obligation.

You can exercise this right by contacting us and asking for your data to be rectified if you believe it is incorrect, out-of-date, or incomplete. You can also update your personal data held by us by logging into your account on our website and updating information.

8. The Right to Erasure

This right is also known as the ‘right to be forgotten’ and gives you the right to have your personal data deleted (or ‘otherwise disposed of’ if, for example, it is kept in paper records rather than electronically).

You can exercise this right by contacting us and asking for your data to be erased.

Please note that the right to erasure is not an absolute right and there are certain circumstances set out in the Data Protection Legislation in which the right does not apply. For example, we may not comply with your request to erase your personal data if we need it to comply with a legal obligation. If any of these circumstances apply, we will explain why your personal data cannot be erased when responding to your request for erasure.

9. The Right to Restrict Processing

You have the right to request the restriction or suppression of your personal data. In practice, this is an alternative to having your personal data erased. This means that you can limit the way in which we use your personal data, while still allowing us to retain it.

Please note that the right to restrict processing is not an absolute right and only applies in certain circumstances as follows:

  1. You have contested the accuracy of your personal data and we are verifying the accuracy of it;
  2. Your personal data has been processed unlawfully and you want us to restrict processing rather than erasing your personal data;
  3. we do not need the personal data any more, but you need us to keep it in order to establish, exercise, or defend a legal claim; or
  4. You have exercised your right to object (see Part 10, below), and we are considering whether our legitimate grounds for processing your personal data override your right to object to us using it.

When processing is restricted, we cannot do anything with your personal data other than store it unless we have your consent to do so or unless one of the following applies:

  1. we need to use your personal data in the establishment, exercise, or defence of legal claims;
  2. we need to use your personal data in order to protect the rights of another person; or
  3. Important public interest reasons justify using it.

You can exercise this right by contacting us and asking for the processing of your data to be restricted.

10. The Right to Data Portability

Where we are processing your personal data either with your consent or for the performance of a contract between us, and we are using automated means of processing (i.e. not using paper files), you have the right to obtain a copy of your personal data in a commonly-used format for use with another organisation. You can also request that we send your personal data directly to another organisation.

This right is designed to enable you to easily move, copy, or transfer your personal data from one organization’s IT system to another organization’s IT system in a safe and secure way, without affecting its usability.

Please note that this right only applies to personal data that you have provided to us. This includes information in your account or profile as well as data that we may obtain from your activities on our website, such as usage history and other factors such as location data. It does not include additional data that we may create based upon the data you have provided or to data that has been anonymised. In some cases, more personal data relating to you may be available under your right of access (see Part 6, above).

You can exercise this right by contacting us and asking either for a copy of your personal data for use with another organisation, or for your personal data to be transferred to that organisation.

11. The Right to Object

Where we are processing your personal data either on the basis of our ‘legitimate interests’ or in the performance of a task carried out in the public interest, you have the right to object to us processing your personal data.

You also have the absolute right to object to us using your personal data for direct marketing purposes.

If you object to us using your personal data for direct marketing purposes, your right to do so is absolute and we have no grounds on which to refuse.

If you object to us using your personal data either on the basis of our ‘legitimate interests’ or in the performance of a task carried out in the public interest, please note that your right to do so is not absolute. When making your request to exercise this right, you must give specific reasons for your objection based upon your particular situation. We can continue using your personal data if we can demonstrate ‘compelling legitimate grounds’ which override your interests, rights, and freedoms; or if the processing is necessary for the establishment, exercise, or defence of legal claims. Additional limitations apply if your personal data is being processed for research purposes.

You can exercise this right by contacting us and stating your objection to the processing of your personal data for the relevant purpose or purposes, providing an explanation if required (see previous paragraph).

12. Automated Decision-Making (Including Profiling)

We carry out certain automated decision-making (i.e. making a decision using automated means only, without any human involvement) using your personal data, as described in our Privacy Notice.

You have the right not to be subject to a decision based solely on automated processing, including profiling, where that decision produces legal or ‘similarly significant’ effects.

You have the right to challenge decisions made in this way and can:

  1. Request human intervention;
  2. Express your own point of view; and
  3. Obtain an explanation from us about the decision and challenge it.

You can exercise this right by contacting us and stating that you wish to ask about or challenge a decision made using your personal data by solely automated means, telling us which of the above (a, b, and/or c) you wish to do (see previous paragraph).

13. Exercising Your Rights

To exercise any of your rights as a data subject, please contact Data Protection Officer (“DPO”): dpo@establishmentlabs.com.

When contacting us to exercise your rights, please be descriptive abouts which rights you are exercising as indicated above.

14. Acknowledgement and Response

We will always respond quickly to your request to exercise any of your rights in relation to your personal data. We will acknowledge receipt without undue delay and will provide a complete response to your request as quickly as possible. Normally, as stated above, this will be within one calendar month of receipt of your request. If additional time is required, we will contact you within the first calendar month to explain why the delay is necessary.

15. Your Right to Complain

If you have any cause for complaint about our use of your personal data, or about our handling of your request to exercise your rights under this Policy, you have the right to lodge a complaint with the supervisory authority in your region.

We would welcome the opportunity to resolve your concerns, however, so we encourage you to please contact us first using the details set out above in Part 13.

16. Changes to this Policy

We may change this Policy from time to time. This may be necessary, for example, if the law changes, or if we change our business in a way that affects personal data protection. This Policy will also be reviewed regularly, at least annually. Any changes will be made available on motiva.health. This Policy was last reviewed on 6 February 2023 and last updated on 6 February 2023.

Reporting Hotline
Careers

ABOUT

PETER

CALDINI

President

PETER

CALDINI

President

Peter Caldini joined the Company as the President in August 2024.  Prior to joining in August, Peter worked as a consultant with the Company’s leadership team to identify efficiencies and cost savings. Before that, Peter was the Chief Executive Officer at Acreage Holdings, Inc., a publicly traded company, from December 2020 to June 2023. Prior to that, he was the Chief Executive Officer and a director at Bespoke Capital Acquisition Corp., a special purpose acquisition corporation, from June 2019 until December 2020. Prior to that, he held positions of increasing responsibility at Pfizer, Inc., including Regional President North America for Pfizer Consumer Healthcare from 2017 to 2019; Regional President EMEA of Pfizer Consumer Healthcare from 2016 to 2017, and leader of the Northern European cluster from 2015 to 2016. From 2009 to 2014, Peter held roles of increasing responsibility at Bayer Consumer Healthcare, including leading the Global Nutritionals Strategic Business Unit and running a sub-region of emerging markets in EMEA. And from 2002 to 2009, he held roles of increasing responsibility at Wyeth Consumer Healthcare in the US and Internationally. Peter received a Masters of International Economics and Management from Bocconi University in Milan, Italy, an MBA from Northeastern University and a BA, Political Science from Boston University.

Learn more about:

ABOUT

ROSS

MANSBACH
General Counsel & Chief Compliance Officer

ROSS

MANSBACH
General Counsel & Chief Compliance Officer

Ross Mansbach joined the company in August 2022 as the General Counsel and Chief Compliance Officer. He was previously at Avanos Medical, Inc., a publicly traded medical device company, where he held positions including Senior Vice President, Interim General Counsel and Corporate Secretary and Vice President, Deputy General Counsel and Corporate Secretary, between November 2014 and March 2022. Prior to that, Mr. Mansbach held positions of increasing responsibility in the Legal Department at Kimberly-Clark Corporation for more than ten years. Earlier in his career, Mr. Mansbach was a partner at the law firm of Powell Goldstein Frazer & Murphy, now known as Bryan Cave. He was also a judicial clerk for a United States District Court judge for the Northern District of Illinois. Mr. Mansbach received his B.A from Yale College and his J.D. from The University of Chicago.

Learn more about:

ABOUT

JEFF

EHRHARDT

SVP & General Manager – North America

JEFF

EHRHARDT

SVP & General Manager – North America

Mr. Ehrhardt joined the Establishment Labs leadership team in April of 2024 after a distinguished career in Plastic Surgery and Dermatology in the U.S. market.  He was most recently VP and General Manager of the U.S. Plastic Surgery and Regenerative Medicine business unit for Allergan Aesthetics, an Abbvie company.  In his 26 plus years at Allergan he held various senior leadership roles such as VP U.S. Commercial Operations, VP of Sales Plastic Surgery & Regenerative Medicine and VP of Sales and Marketing, U.S. Dermatology.  Notably, he was head of Dermatology Sales for the launch of Botox Cosmetic, acquisition and merger of Lifecell into the U.S. Plastic Surgery organization, acquisition and launch of Aczone®, an acne product, and the launch of the Inspira® line of breast implants.   In his role at Establishment Labs, he will be responsible for the commercialization of the Motiva® Femtech line of breast aesthetics devices in both the U.S. and Canada.   He holds undergraduate degrees in Finance and Marketing from the University of Cincinnati and an M.B.A. from Xavier University.

Learn more about:

ABOUT

PAUL

RODIO

Chief Operating Officer

PAUL

RODIO

Chief Operating Officer

Paul is a seasoned Operations Executive with over 30 years of global experience across supply chain, manufacturing and operations within Med Device, Consumer Packaged Goods, and Industrial industries.

Paul joined Establishment Labs on December 1, 2022 from Cardinal Health, where he led the Medical Segment’s Global supply chain planning, procurement, deployment, service and repair, medical device reprocessing operations, and key account CPFR as Senior Vice President Global Planning and Operations.  Prior to that, he was Vice President Supply Chain, Contract Manufacturing for Medtronic and Covidien.  Earlier in his career, he held positions of increasing responsibility at Newell Rubbermaid, Evenflo, Arthur Anderson LLP, and Swagelok.

Learn more about:

ABOUT

ROSALYN

COLE D’INCELLI

SVP, Global Clinical, Medical & US Regulatory Affairs

ROSALYN

COLE D’INCELLI

SVP, Global Clinical, Medical & US Regulatory Affairs

Rosalyn d’Incelli has been a part of Establishment Labs® since May of 2020 as the company’s Head of Clinical and Medical Affairs, bringing to the company over 20 years of medical device experience. In this role, she drives global clinical and medical strategy and execution and leads U.S. Regulatory Affairs. Prior to joining us, she was with Sientra Inc., for 11 years as the Vice President of Clinical and Medical Affairs. She was responsible for U.S. PMA approval, Medical Education, PR, Publications, and the company’s scientific content. She represented the company with FDA, media, and medical education events and congresses. Preceding Sientra, Ms. d’Incelli held similar roles with PMA approvals at Mentor/Johnson & Johnson and Inamed (now Allergan/AbbVie). She holds a B.A. in communication/market research from the University of California, Santa Barbara, and is board certified in SoCRA and RAP.
Learn more about:

ABOUT

SALVADOR

DADA

Head of Special Projects

SALVADOR

DADA

Head of Special Projects

Mr. Dada was one of the founding members of the company back in 2004. Salvador initially led the implementation of Establishment Labs® operations in Costa Rica and the successful certification of the Motiva Implants® product family by the European Union and other high vigilance countries.

In February 2016 he was appointed as our Chief Operating Officer where he led the expansion of the operations to Brazil, Belgium, and in recent years, to several other European countries where direct commercial operations were launched. Due to health issues, he resigned from his position as COO and now serves as Head of Special Projects. Mr. Dada served in various engineering roles at Allergan Medical from 2007 to 2009 and in a variety of production and manufacturing roles at Establishment Biotech, S.A. from 2004 to 2006.

He has an undergraduate and licentiate degree in Industrial Engineering from the University of Costa Rica.

Learn more about:

ABOUT

ROBERTO

DE MEZERVILLE

Chief Technology Officer

ROBERTO

DE MEZERVILLE

Chief Technology Officer

Since 2009, Roberto has risen through several positions in our company, in the areas of quality management, research, regulatory and clinical affairs, and has been our CTO heading Research, Development, and Innovation since January 2018.

Roberto has led several impactful research projects that have been key to the science-based design of our FemTech technologies, and has authored peer-reviewed publications. From 2006 to 2009, served in various engineering and quality manager positions with Allergan Medical Costa Rica.

He has a bachelor’s degree in Business Administration from Universidad Interamericana de Costa Rica and a bachelor’s degree in Industrial Environmental Health and Safety Engineering from Instituto Tecnológico de Costa Rica.

Learn more about:

ABOUT

RAJ
DENHOY

Chief Financial Officer

RAJ

DENHOY

Chief Financial Officer

Raj has been part of Establishment Labs® since February 2021. Before his current role as Chief Financial Officer, he served as the company’s Head of Strategy and Investor Relations. Raj joined the company from Jefferies Group, LLC where he was a Managing Director and led the U.S. medical device research team for eleven years, including coverage of Establishment Labs®.

He covered the medical device industry as an equity research analyst for over twenty years. Raj has an impressive academic portfolio, including a bachelor’s degree in biology from UC Berkeley, a master’s degree in Physiology from Georgetown University, and an MBA from Cornell University.

Learn more about:

ABOUT

IVAN

BILIC

Senior Vice President of Commercial Operations – OUS

IVAN

BILIC

Senior Vice President of Commercial Operations – OUS

Mr. Bilic has been part of Establishment Labs since April 8, 2019, and is dedicated to advancing women’s health through innovative technology. His career highlights include roles as senior commercial director for European distribution markets, vice president for EMEA, and his current position as senior vice president for OUS. Notable accomplishments include restructuring the commercial function and transforming the German market. In his current role, Mr. Bilic strategically leads Establishment Labs’ commercial efforts, overseeing both the channel and direct markets and shaping B2B and B2B2C strategies for market leadership. He represents Establishment Labs in the non-U.S. plastic surgery market and drives innovative marketing approaches globally. Prior to joining Establishment Labs, he held key positions at Polytech and Allergan and holds a Master of Business Administration from Hult International Business School.

Learn more about:

ABOUT

ROBERT

LANGER

PhD

ROBERT

LANGER

PhD

Robert Langer is an Institute Professor at MIT (there are 13 Institute Professors at MIT; an Institute Professor is the highest honour awarded to a faculty member). His h-index of 232 is the highest of any engineer in history. He has over 1,130 issued and pending patents which have been licensed or sublicensed to over 300 companies. He served as Chair of the FDA’s SCIENCE BOARD (highest advisory board) from 1999-2002.  Langer is one of a very few individuals elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors.  He is one of four living individuals to receive both the US National Medal of Science and the US National Medal of Technology and Innovation.  In 2015, Dr Langer received the Queen Elizabeth Prize for Engineering.  He has also received the Draper Prize (considered the engineering Nobel Prize), Albany Medical Center Prize, Wolf Prize for Chemistry, Millennium Technology Prize, Priestley Medal (highest award of the American Chemical Society),  Gairdner Prize, Kyoto Prize and the Lemelson-MIT Prize, for being “one of history’s most prolific inventors in medicine”. He holds 29 honorary doctorates including honorary degrees from Harvard and Yale.

ABOUT

PROF. MICHAEL

ATLAN

MD & PhD

PROF. MICHAEL

ATLAN

MD & PhD

Prof. Michael Atlan MD, Ph.D. is currently the chief of the Plastic and Reconstructive Surgery Department at TENON Hospital and a Professor at the Sorbonne Medecine Universite.

His main interests are Aesthetic Breast Surgery, breast reconstruction with ADM, Free Flaps for breast reconstruction, and Breast Cosmetic Surgery (anatomic implants, Fat Grafting). His areas of expertise include breast implant surface, the evaluation of new devices in plastic surgery, and Facial Aesthetic Surgery.

He is one of the founders of the CAMPUS CHAMPS ELYSEES.

ABOUT

ARDESHIR

BAYAT

MD & PhD

ARDESHIR

BAYAT

MD & PhD

Prof. Ardeshir Bayat is Director of the Medical Research Council Wound Healing Unit and professor at the University of Cape Town, Cape Town in South Africa. He is considered an expert in wound healing, cutaneous repair and skin scarring, with internationally recognised expertise in implant surface technology, fibrosis and capsular contracture. He trained as a surgeon-scientist with a PhD in molecular genetics of fibrosis. He has published extensively in peer-reviewed scientific literature (in excess of 500 articles to date). He is regularly an invited speaker at both national and international tissue repair conferences (over 600 conferences to date) and serves on the editorial boards of several journals.

His team have created and patented novel biomimetic surfaces and continue to work on developing models to understand the process of cell surface interaction/capsular fibrosis and its modulation related to implant surfaces. His investigative work has enabled translation of basic science to therapeutic developments of direct relevance to both cosmetic patients and industry.

ABOUT

BRIAN

KINNEY

MD & Eng

BRIAN

KINNEY

MD & Eng

Dr. Brian M. Kinney is a Clinical Associate Professor of Plastic Surgery at the University of Southern California in Los Angeles and a reputable board certified plastic surgeon. Dr. Kinney has served as President of the Plastic Surgery Educational Foundation of the US (PSEF), Chairman of the Board of Trustees of the American Society of Plastic Surgeons (ASPS), Deputy Secretary General of the International Confederation of Aesthetic, Plastic and Reconstructive Surgeons (IPRAS), Board member of the American Society for Aesthetic Plastic Surgery (ASAPS), part of the International Society of Aesthetic Plastic Surgeons (ISAPS), Co-Founder and Board of directors of the International Society of Plastic Regenerative Surgery (ISPRES), as well as chairman and Medical Director of Thermi. Dr. Kinney has one of the top plastic surgery practices in southern California for over twenty-five years and is also a staff member of many major hospitals in West Los Angeles, such as St. John’s Hospital and Health Center and Cedars-Sinai Medical Center. Dr. Kinney earned his bachelor’s degree (Biomedical/Mechanical Engineering) and master’s degree (Mechanical/Electrical Engineering) after completing the Harvard/MIT Health Sciences and Technology program. He then attended medical school at Tulane University and trained in general surgery and plastic surgery at UCLA in Los Angeles, CA, USA.

ABOUT

ARIKHA

MOSES

MD & PhD

ARIKHA

MOSES

MD & PhD

Arikha is an experienced medical device executive and entrepreneur, whose companies developed products that have been implanted in millions of patients worldwide.  She was the founder and CEO of Galatea Surgical (now owned by Becton Dickinson), guiding the company from inception, through clinical studies and the commercial release of GalaFLEX© for soft tissue reinforcement.  She was also the founder and CSO of TyRx (now Medtronic Infection Control), which commercialized antibiotic eluting products for the prevention of infection associated with indwelling devices.  Over more than 20 years in the industry, Arikha has cultivated deep expertise in resorbable surgical products and the development of solutions to complications associated with implantable devices. Arikha is currently an investor and board member of several privately held medical companies and nonprofit organizations.  She has a PhD in Chemistry from Yale and a BA in Chemistry from Brandeis University.

ABOUT

DR MARCOS

SFORZA

MD

DR MARCOS

SFORZA

MD

Prof Marcos Sforza, MD Marcos Sforza is one of the most renowned lecturers and researchers in the realm of Plastic Surgery. He is a Senior Professor of Plastic Surgery and regenerative medicine at the SESA University, Brazil, a Professor of Cosmetic Surgery UNIFESO School of Medicine, responsible for the Elective internship in Cosmetic Surgery in the UK and a Fellow of the Royal College of Surgeons of England. 

Prof Sforza is a registered member of the International Society of Aesthetic Plastic Surgery–ISAPS, the Brazilian Society of Plastic Surgery, the American Society of Plastic Surgery and the American Society of Aesthetic Plastic Surgery. He has more than 100 peer-reviewed published papers and lectures all around the world as the world’s leading authority in Nanosurfaced silicone breast implants. He is also the Editor in Chief of the Journal of Surgery and Annal of Plastic and reconstructive surgery Journals.

ABOUT

DR ALEXANDRE

MUNHOZ

MD

DR ALEXANDRE

MUNHOZ

MD

Dr. Alexandre Mendonça Munhoz, M.D., PhD. Is Assistant Professor of Plastic Surgery, Breast Surgery Division of Plastic Surgery at University of São Paulo School of Medicine in Sao Paolo,Brazil and a full member of the Brazilian Society of Plastic Surgery (SBCP). He participates as a guest member of the international consultants of Plastic and Reconstructive Surgery and Breast Journal since 2006.

In the period of 2010-2014 Dr. Munhoz took over a role of a permanent member of the editorial board of the Annals of Plastic Surgery and the coordination of the National Commission of Breast Reconstruction of Brazilian Society of Plastic Surgery.

Dr.Munhoz currently has 27 scientific awards related to plastic surgery research, 145 published scientific papers, being 124 indexed in PubMed platform, 93 publications as a first author and in the area of aesthetic and reconstructive breast surgery, which resulted in about the 2967 citations with H-Index of 29.

In 2013, he became Head of the Breast Reconstruction Department of the Cancer Institute of São Paulo (ICESP). In 2015, Dr. Munhoz took over the Department of Plastic Surgery of the Moriah Hospital. In 2016, he was elected by American Society of Plastic Surgery (ASPS) as Associated Editor of Plastic and Reconstructive Surgery Global Open Journal. In 2022, Dr. Munhoz became an International member of American Society of Plastic Surgery (ASPS) and a full member of International Society of Aesthetic Plastic Surgery (ISAPS).

ABOUT

DR DENNIS

HAMMOND

MD

DR DENNIS

HAMMOND

MD

Dr. Dennis Hammond, a board-certified plastic surgeon by the American Board of Plastic Surgery, is one of the world’s most recognized and respected authorities in breast aesthetic and reconstructive surgery. He is a member of and has served on numerous committees for the American Society of Plastic Surgeons (ASPS) as well as for the American Society for Aesthetic Plastic Surgery (ASAPS), and is a member of the prestigious American Association of Plastic Surgeons.

Dr. Hammond has co-edited one of the most influential textbooks in plastic surgery along with his friend and colleague Dr. Scott Spear from Georgetown University in Washington DC. He has authored many scientific papers, and serves as a reviewer for scientific articles for Aesthetic Plastic Surgery, Plastic and Reconstructive surgery, and the Journal of Aesthetic Surgery.

Dr. Hammond has written “Atlas of Aesthetic Breast Surgery“, first published in 2009, a book which became a gold standard on how to perform new and innovative techniques for surgically and artistically augmenting, reshaping, lifting, and reducing the breast.

ABOUT

DR NIAMH

CORDUFF

MD

DR NIAMH

CORDUFF

MD

Dr Niamh Corduff qualified from Charing Cross Medical School, the University of London, in 1984 and subsequently did her basic surgical training in the UK before emigrating to Australia in 1988. Dr Corduff completed her specialist plastic surgical training in Melbourne Australia and in 1993 became a Fellow of the Royal Australasian College of Surgeons. With more than 2 decades of experience, this Australian surgeon is a member and former president of the Australasian Society for Aesthetic Plastic Surgery and an honorary member of the Australian Society of Plastic Surgeons. Dr Corduff developed a special interest in breast surgery and since 2000 her surgical practice was focused solely on aesthetic and reconstructive breast surgery. She has published and lectured on aesthetic breast surgery both locally and internationally.

ABOUT

DR FEDERICO

MAYO

MD

DR FEDERICO

MAYO

MD

Born in Spain in 1967, Dr. Mayo holds a degree in medicine and surgery from Universidad Complutense de Madrid, a doctorate in research skills from Universidad Complutense de Madrid, and a medical specialty in plastic aesthetic and reconstructive surgery since 2001, recognized by the UK. He is a member of the General Medical Council, validated in Switzerland and has professional experience in Zurich and currently in Madrid. 

He is the author of chapters in specialty books and his works have been published in renowned journals, such as Aesthetic Plastic Surgery and Plastic and Reconstructive Surgery. Dr. Mayo is an active member of the scientific society, including the Sociedad Española de Cirugía Estética y Plástica, the Asociación Española De Cirugía Estética, the International Society of Aesthetic Plastic Surgery, and the American Society of Plastic Surgery. He is a reviewer for the Aesthetic Plastic Surgery Journal and has patented ideas applicable in breast implant manufacturing. He has completed over 12,000 surgical interventions as primary surgeon and has implanted over 10,000 breast implants in more than 20 countries around the world as part of conferences, Masterclasses, and other scientific events.

ABOUT

JEFFREY
BETTINGER
Global Head of People

Jeffrey Bettinger joined Establishment Labs® in November 2021 from Nu Skin, a global leader in beauty and wellness, where he served as the Chief People and Places Officer. In addition, he held a variety of executive and senior leadership roles in medical devices, financial services, pharmaceuticals, and engineering.

Some of his past employers are USAA, Petco, State Farm, Fluor, and Walmart. He has had the honor of receiving regional and national recognition for leadership development and culture transformation. Moreover, he has been published on a variety of human capital topics. Mr. Bettinger has an extensive academic background, starting with a bachelor’s degree in communication, a master’s degree in Organizational Communication and Educational Administration from Idaho State University, and a Master’s in Business Administration from Liberty University.

Learn more about: